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Abstract 
Background – Chemotherapy-induced left ventricular cardiotoxicity is associated with many 
cancer treatments; however, what is less known is how these treatments affect vascular health 
and autonomic control of blood pressure. Arterial stiffness and cardiovagal baroreflex sensitivity 
(BRS) are indicators of cardiovascular health and may provide insight into the adverse effects of 
anti-cancer chemotherapy. Therefore, the primary aims of the present study were to evaluate 
carotid artery stiffness and arterial BRS in cancer patients currently being treated with adjuvant 
chemotherapy.  
 
Methods – We performed a cross-sectional, case-control study involving 9 cancer patients and 9 
age- and sex-matched controls. Carotid artery stiffness was assess via 2D ultrasonography. 
Cardiovagal BRS was assessed from the spontaneous changes in beat-to-beat time series of R-R 
interval and systolic blood pressure via the cross correlation technique.  
  
Results – Our findings indicated a significant decrease in cardiovagal BRS in cancer patients 
compared to controls (4.7 ± 0.6 vs 9.2 ± 1.7 msec mmHg-1 respectively, P = 0.02). Carotid artery 
β-Stiffness was significantly higher in the cancer patients compared to control participants (9.2 ± 
1.2 vs 6.6 ± 0.74 U respectively, P = 0.05). 
 
Conclusions – These data suggest that anti-cancer chemotherapy elicits significant decreases in 
the autonomic control of blood pressure and arterial stiffness, leaving cancer survivors with an 
increased risk of future cardiovascular disease. 
iv 
 
Table of Contents 
 
List of Figures v 
List of Table      vi 
Acknowledgements        vii 
Dedication        viii 
Chapter 1 - Introduction           1 
Chapter 2 - Methods 3 
Participants 3 
Experimental Design 3 
Experimental Measurements 4 
Statistics 5 
Chapter 3 - Results 7 
General Characteristics 7 
Chapter 4 - Discussion 13 
Considerations and Limitations 18 
Conclusions 18 
References 20 
 
  
v 
 
List of Figures 
 
Figure 1 Beta-Stiffness Box and Whisker Plot 10 
Figure 2 Cardiovagal BRS Box and Whisker Plot 11 
Figure 3 Cardiovagal BRS vs Beta-Stiffness Linear Regression 12 
 
  
vi 
 
List of Tables 
 
Table 1. Cancer Patient Treatment Characteristics. 6 
Table 2. Participant Characteristics. 8 
Table 3. Carotid Artery Imaging 9 
 
  
vii 
 
Acknowledgements 
Special thanks to all the members of Dr. Ade’s Cardiovascular Physiology Lab, 
especially Shelbi Sutterfield and Jacob Caldwell for their consistent hard work on this project. 
 
  
viii 
 
Dedication 
This project is dedicated to Jonathan Paul Frye and Edith Kay Billhimer. Cancer is a 
disease that doesn’t discriminate, it just takes and it takes. You two know this from first-hand 
experience, and I never forget that. Every patient I met I saw you two in their eyes. You inspire 
me to serve them as I would serve you. I love you guys. 
 
 
1 
 
Chapter 1 -  Introduction 
Anti-cancer chemotherapy is a common treatment option for numerous types of cancer 
that, while successful in terms of cancer survival, is associated with both acute and chronic 
cardiotoxicity (23, 25, 57). As such, anti-cancer chemotherapy is associated with increased 
cardiovascular disease risk, with cardiovascular disease being the second leading cause of 
mortality in breast cancer survivors (25, 57). While chemotherapy-induced left ventricular 
cardiotoxicity is well established (9, 29), certain types of chemotherapy have been linked to 
vascular abnormalities (38, 57), peripheral neuropathy (54, 7, 50), autonomic dysfunction (23, 
50), and increased arterial stiffness (5, 11, 41). While current practices rely on traditional 
cardiovascular risk factors (46) to assess cardiovascular health, new methods of evaluating 
integrative cardiovascular function in cancer patients will provide additional insight into the 
early cardiotoxic effects of chemotherapy. 
The arterial baroreflex is a tonically active feedback control system that is critical in the 
beat-to-beat regulation of arterial blood pressure by indirectly detecting changes in blood 
pressure via mechanoreceptors located in the walls of the carotid arteries and the aorta (44). This 
information is integrated in the nucleus tractus solitarius of the medulla and used to mediate both 
parasympathetic and sympathetic signaling to the heart and peripheral vasculature (32, 58). 
Recently, decreases in arterial baroreflex sensitivity (BRS) have been shown to occur with 
healthy aging (22, 37, 44), hypertension (22, 35), and during heart failure (47). Moreover, 
decreases in BRS have been identified as an independent risk factor for both acute and chronic 
cardiovascular problems, including increased morbidity and mortality (33, 47). Evidence 
suggests that these decreases in BRS observed in these populations could be due, in part, to a 
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stiffening of the carotid arteries (12, 43, 44). Increased arterial stiffness will decrease the 
magnitude of distention for a given increase in arterial pressure, thus decreasing the mechanical 
deformation of the baroreceptors (43). Therefore, any condition that alters the visioelestic 
characteristic of the vessel wall and the extravascular elements that connect it to the 
mechanosensitive nerve endings will potentially alter arterial baroreflex activity. Stiffening of 
the large arteries is present following chemotherapeutic cancer treatment (5, 11, 26, 41). Miza-
Stec et al. (41) demonstrated in middle aged women that decreased arterial compliance and 
increased arterial stiffness are present within six months following chemotherapeutic treatment 
for breast cancer. Similarly, Chaosuwannakit et al. (11) also showed a significant increase in 
arterial stiffening over only a four month period following chemotherapy, but included a broader 
range of cancer patients (e.g., breast, lymphoma, or leukemia) into their study.  
Despite these reported increases in arterial stiffness it is currently unknown if arterial 
BRS is decreased in cancer patients currently undergoing chemotherapy and if this is associated 
with increases in arterial stiffness.  Therefore, the primary aims of the present study were to 
evaluate carotid artery stiffness and arterial BRS in cancer patients currently being treated with 
adjuvant chemotherapy. We hypothesized that cancer patients receiving chemotherapy would 
experience decreased arterial BRS and increased arterial stiffness when compared to age and sex 
matched healthy subjects.  
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Chapter 2 -  Methods 
Participants 
 This study utilized a cross-sectional, matched case-control design with 8 patients 
diagnosed with cancer recruited from local oncology clinics. At the time of the study all patients 
were currently being treated with chemotherapy or a combination of chemotherapy and radiation 
as confirmed by their current oncologist/family practitioner (Table 1). Information on surgery 
was not obtained. Patients had been treated for cancer for an average of 4 months (range 1-13 
months). Control group participants were matched for sex and age to individuals in the cancer 
group. Exclusion criteria for groups included; history of smoking, current smoker, diabetes, 
cardiovascular or cardiorespiratory diseases, and had received prior treatment for cancer. Current 
level of physical activity was determined using the International Physical Activity Questionnaire 
(47). Informed consent was obtained from all individuals included in the study according the 
Kansas State University (Manhattan, KS) Institutional Review Board for Research Involving 
Human Subjects requirements. 
 
Experimental Design 
 The experiments were performed during a single session in a temperature-controlled 
clinical environment (~20-22oC), at least 4 hours after last meal and last caffeinated beverage, 
and > 12 hours after strenuous physical activity. The participant was placed in the supine 
position and allowed to rest for 5-10 minutes. Following this rest period the participant was 
instrumented for continuous beat-by-beat blood pressure and heart rate measurements. At least 
10 minutes of resting baseline data were recorded during spontaneous breathing to assess 
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spontaneous cardiovagal BRS. Subsequently, ultrasonography of the common carotid artery was 
performed for the assessment of carotid artery stiffness. 
 
Experimental Measurements 
Systolic (SBP), diastolic (DBP), mean arterial pressure (MAP), and heart rate (HR) were 
measured on a beat-by-beat basis via a calibrated finger photoplethysmography system 
(Finometer Pro; Finapress Medical Systems, Amsterdam, The Netherlands). Brachial artery 
blood pressure was measured by an automated sphygmomanometer (Finometer Pro) and used to 
calibrate the reconstructed arterial pressure waveform via a “return-to-flow” procedure. In all 
instances, arterial pressure recordings were performed at heart level. 
Spontaneous cardiovagal BRS was evaluated by examining the beat-to-beat time series of 
R-R interval and SBP via the cross correlation technique as previously described (45). Briefly, 
10 second windows of simultaneous R-R interval and SBP were spline interpolated and 
resampled at one second intervals and used to identify arterial baroreflex sequences were 
identified as sequences of consecutive beats where R-R interval and SBP changed in the same 
direction. The slope between R-R interval and SBP was recorded as a BRS estimate if the r2 ≥ 
0.8 and was significant at P ≥ 0.01. The biggest advantage of this method of BRS is that it 
provides a larger sampling size than other sequential methods, while having half the estimation 
variance (45). 
 Local cross-sectional carotid artery diameter was measured with a commercial 2D 
ultrasound system via a high-resolution phased-array transducer operating at 10M Hz and 
simultaneous ECG recordings. This system allows for sequential measurements of arterial wall 
motion across several cardiac cycles. Each participant had the left carotid artery imaged for a 
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single 15 second interval while at rest with the transducer placed proximal to the carotid 
bifurcation. Maximal (i.e., end-systolic) and minimal (i.e., end-diastolic) luminal diameter were 
time aligned with photoplethysmography blood pressure measurements obtained during 
acquisition of the carotid artery measurements. These measures allowed for the calculation of 
mechanical strain and stiffness of the carotid artery (19, 22). For our various calculations, the 
following abbreviations will be used; carotid systolic diameter (CSD), carotid diastolic diameter 
(CDD), and carotid pulse pressure (CPP). 
β-Stiffness was calculated as: 
Ln (SBP/DBP)/((CSD -CDD)/CDD) 
Carotid Artery cross-sectional compliance was calculated as: 
π x ((2 x CDD) x (CSD-CDD)) + (CSD-CDD)2)/4 x CPP 
 
Statistics 
 Data were entered into SPSS 21 for analysis. Paired t-tests were used to identify 
differences between the control and cancer groups for all measured outcomes as previously 
described for matched case-control studies (65). Linear regression analysis and Pearson product 
moment correlations were used to evaluate the relationship between BRS and β-stiffness. All 
results are expressed as mean ± standard error. Differences were considered statistically 
significant when P ≤ 0.05. 
 
 
 
  
6 
 
 
 
Table 1. Cancer Patient Treatment Characteristics 
ID 
no. 
Age 
(yrs) 
Sex Cancer Type 
Chemotherapy treatment 
Cumulative dose to date 
Months of 
Treatment 
1 63 F Pancreatic 
-Fluorouracil 26000 mg  
-Oxaliplatin 680 mg 
-Xeloda 23000 mg 
5 
2 50 M 
Non-Hodgkin's 
Lymphoma 
-Bendamustine 1080 mg   
-Rituximab 2400 mg 
2 
3 39 F 
Neuroendocrine 
Tumor 
-Carboplatin 7150 mg   
-Etoposide 7200 mg  
-Fluorouracil 110,550 mg  
-Oxaliplatin 2200 mg 
12 
4 74 M 
Non-Hodgkin’s 
Lymphoma 
-Cyclophosphamide 6000 mg  -
Doxorubicin 400 mg  
-Rituximab 3200 mg  
-Vincristine 8 mg  
5 
5 53 F 
 
Breast 
-Cyclophosphamide 4760 mg              
-Doxorubicin 476 mg    
-Paciltaxel 400 mg 
5 
6 54 F Breast 
-Doxorubicin 350 mg 
-Paclitaxel 350 mg 
3 
7 60 F 
 
Breast 
-Docetaxel 130 mg    
-Trastuzumab 367 mg  
2 
8 69 M Prostate -Docetaxel 150 mg  1 
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Chapter 3 -  Results 
General Characteristics 
Participants receiving cancer treatment were diagnosed with breast cancer (n=3), 
lymphoma (n=2), pancreatic (n=1), or a metastatic tumor. Therapies included doxorubicin (n=3), 
fluorouracil (n=2), cyclophosphamide (n=2), docetaxel (n=2), carboplatin (n=2), rituximab 
(n=2), oxaliplatin (n=2), pacilltaxel (n=3), xeloda (n=1), bendamustine (n=1), etoposide (n=1), 
vincristine (n=1), trastuzumab (n=1). There were no significant differences in age, height, 
weight, and body mass index (BMI) between cancer patients and control participants. Resting 
SBP and DBP were also not different between groups. Of the cancer patients two (25%) were 
classified as inactive and six (75%) as minimally active. The control group was composed of one 
(13%) inactive and seven (87%) minimally active individuals. 
Table 2 summarizes participant characteristics for both groups, while Table 3 summarizes 
carotid imaging results. Differences in carotid artery stiffness are illustrated in Figure 1. Carotid 
artery β-Stiffness was significantly higher in the cancer patients compared to control participants. 
However, carotid artery cross-sectional compliance was not significantly different between 
groups (P = 0.07). During the imaging of the carotid artery, arterial pulse pressure was not 
significantly different between groups. Individual and mean spontaneous cardiovagal BRS data 
are illustrated in Figure 2. Cancer patients had a significantly lower cardiac BRS compared to 
control participants (4.7 ± 0.8 vs 9.2 ± 1.7 msec mmHg-1 respectively, P = 0.017). A significant 
negative correlation was observed between carotid artery β-Stiffness and cardiovagal BRS 
(Figure 3, r = -0.61, P = 0.007).  
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Table 2: Participant Characteristics  
 Control (n = 8) Cancer (n = 8) P-value 
Age, years 54 ± 3 58 ± 4 0.16 
Sex, M/F 3/5 3/5 - 
Height, cm 169.3 ± 2.4 168.1 ± 3.8 0.66 
Weight, kg 70.3 ± 6.1 82.9 ± 9.1 0.27 
BMI, kg/m2 24.6 ± 1.5 29.1 ± 3.5 0.26 
Systolic BP, mmHg 146 ± 5 142 ± 4 0.53 
Diastolic BP, mmHg 79 ± 2 75 ± 3 0.28 
Data are presented as mean ± SE; BMI, body mass index  
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Table 3.  Carotid Artery Imaging  
 Control (n = 8) Cancer (n = 8) P-value 
Carotid artery diameter at 
end-diastole, cm 
0.67 ± 0.04 0.72 ± 0.04 0.36 
Pulse Pressure, mmHg 67 ± 3 67 ± 5 0.95 
β-Stiffness Index 6.6 ± 0.7 9.2 ± 1.2 0.05 
Data are presented as mean ± SE  
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Figure 1- β-stiffness box and whisker plot for cancer and control groups. A significant 
increase in β-Stiffness was observed in the cancer patients compared to controls. Each data point 
is indicative of a single participant. Box plots summarize the distribution of values. The ends of 
the box are the 25th and 75th quartiles, with the center line indicating the median value. 
Whiskers indicate the 90th and 10th percentiles.    
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Figure 2- Cardiovagal baroreflex sensitivity box and whisker plot for cancer and control 
groups. Baroreflex sensitivity was significantly decreased in the cancer group compared to 
controls. Each data point is indicative of a single participant. Box plots summarize the 
distribution of values. The ends of the box are the 25th and 75th quartiles, with the center line 
indicating the median value. Whiskers indicate the 90th and 10th percentiles.    
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Figure 3 – Linear regression between cardiovagal baroreflex sensitivity (BRS) and carotid 
artery β-stiffness. The linear regression analysis revealed a significant relationship between 
carotid artery stiffness and cardiovageal baroreflex sensitivity (BRS) with a P = 0.007, indicating 
that sensitivity was decreased as stiffness increased.  
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Chapter 4 -  Discussion 
The present study addressed the question of whether the use of chemotherapeutic 
treatment in cancer patients resulted in arterial stiffening and changes in arterial blood pressure 
control in cancer patients compared to healthy controls. Previous investigators have identified 
that within months of finishing chemotherapeutic treatment patients demonstrate evidence of 
cardiac and arterial damage (11, 26, 41). Our work expands on these findings and revealed that 
anti-cancer chemotherapy can have several detrimental effects on cardiovascular health within 
weeks of starting treatment. One such effect seen was an increase in carotid artery stiffness, 
which would decrease the ability of the arteries to distend when faced with increases in flow. 
This increased stiffness was quantified via calculation of both a β-stiffness coefficient and cross-
sectional arterial compliance. In addition, decreases in spontaneous cardiovagal BRS was 
decreased in our group of chemotherapy treated cancer patients and modestly associated with the 
observed decreased compliance. These findings support our hypothesis that A) arterial stiffness 
would be increased in chemotherapy patients compared to healthy controls and B) the BRS 
would be decreased in chemotherapy patients compared to healthy controls.  
Increased arterial stiffening is concerning because of the connection between increased 
stiffness and risk of cardiovascular disease (48). Even in otherwise healthy functioning older 
adults, increased arterial stiffness is predictive of future cardiovascular related mortality, chronic 
heart failure, and stroke occurrences (43). Arterial stiffening will naturally occur with age, and 
ultimately can be best avoided with exercise (44). Our data suggests that independent of age, 
treatment with chemotherapy significantly increases arterial stiffness, suggesting an overall 
worsening of the cardiovascular disease risk profile.  
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Similar to our work, Mizia Stec et al. (41) demonstrated an increased arterial stiffness 
following adjuvant chemotherapy in breast cancer patients, while Chaosuwannakit et al. (11) 
showed similar results in breast, lymphoma, and leukemia patients receiving chemotherapy. 
Additionally, Jenei et al. (26) has shown increased arterial stiffening in childhood cancer 
survivors. Our data support these previous findings, showing increases in arterial stiffness in our 
group of chemotherapy patients compared to healthy controls. 
The development and progression of arterial stiffness is a multifactorial process that 
involves the interaction between structural and cellular elements of the vessel wall, specifically 
the tunica adventitia, vascular smooth muscle, and the endothelium. The tunica adventitia 
consists of collagen fibers for structural integrity and elastin for distensability. A proper ratio of 
these two is required for the arteries to properly function. In both normal aging (30, 46, 52) and 
with cardiovascular disease progression (48) we see increases in arterial stiffness as well as an 
increase in the collagen:elastin ratio. Over time and with increased wall stress, degradation of 
elastin can occur (52) as well as increases in collagen content (56). This decay in elastin can 
occur due to calcium binding to the elastin fibers (60) and dysregulation of elastases (52, 64, 61). 
Direct binding of calcium ions to elastin causes calcification and decreases the elastic properties 
of the elastin. Increased activity of matrix elastases with age (64) results in more elastin fibers 
being degraded, which has been shown to accompany an increase in collagen:elastin ratio and 
decrease in functionality (29, 59, 19). Lastly, age related changes in amino acid profile decrease 
the availability of the amino acids desmosine and isodesmosine (63), which are required for 
proper crosslinking of elastin fibers, and with their decreases in availability result in a decrease 
in the elastic properties of elastin. While elastin is severely inhibited by disease and age, collagen 
concentrations increase. This can occur as a result of phenotype changes at the level of the 
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smooth muscle resulting in an increase in collagen formation across multiple layers of the artery 
(28), as well as through increased glycation of collagen fibers (53, 56). 
The vascular smooth muscle is responsible for maintaining tone in the arteries and can be 
adversely altered in a variety of ways. Phenotypic changes of the smooth muscle can occur after 
prolonged periods of stress (28). This phenotypic change is often accompanied by cellular trans-
differentiation, which is considered the main driving factor for increases in arterial calcification 
(28). This is because it changes the smooth muscle into a mediator of bone formation, causing 
increased calcification throughout the artery (28). Cellular trans-differentiation appears to be 
induced by a variety of factors that can be detrimental to the vasculature, namely; elastin 
degradation, increased reactive oxygen species, and fibrosis (28).  
Endothelial changes in the arteries affect signaling pathways that cause some of the 
changes examined in the tunica adventicia and smooth muscle. The endothelium is an important 
site for the nitric oxide (NO) signaling pathways, whose effects are wide in scope. Decreased NO 
bioavailability is present with chronic inflammation (28), increase reactive oxygen species (28) 
and is considered associated with mechanisms that contribute to arterial stiffening (31). These 
increases in reactive oxygen species could then be a driving force for the cellular trans-
differentiation occurring the smooth muscle. Additionally, chronic inflammation has been shown 
to decrease the production of psrostacyclin, which usually assists in vasodilation and inhibits 
platelet aggregation (42, 13).  
There are a variety of possible mechanisms for this increased arterial stiffness with 
chemotherapy. First, increased inflammation resulting from the therapy could be impacting 
arterial stiffness in a similar way to what’s been seen in other chronically inflamed populations 
(3, 46).  Second, peripheral neuropathy has been identified as a possible side effect to a variety of 
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chemotherapeutic drugs, which could be detrimental to BRS (39, 40). Lastly, oxidative stress 
could be a mechanism as current evidence suggests that antioxidant supplementation can dampen 
these responses in certain models (6, 15). As seen in Table 1, a variety of chemotherapeutic 
drugs were used by our patient population and many of these drugs are associated with 
cardiovascular complications. Anthracyclines are associated with both acute and chronic 
progressive cardiomyopathy as well as increases in reactive oxygen species (15, 61), and were 
used by four of our patients.  Two of our patients were treated with antimetabolites, which have 
been associated with increased risk of angina pectoris, myocardial infarctions, hypotension, and 
arrhythmia (17, 34, 49). Antimicrotubule agents were used on five subjects and have been 
associated with hypotension, arrhythmia, and neuropathy (4, 51). Monoclonal antibodies have 
been associated with hyper/hypotension, angioedema, and arrhythmias (20). These drugs were 
administered to three of our patients. Increased risk of chronic heart failure, neuropathy, and 
myocarditis have been associated with use of alkylating agents (18, 21), which five patient were 
administered. While there certainly is variety in the types of chemotherapy drugs administered to 
our patients, all drugs clearly have shown some sort of side effect that is detrimental to arterial 
function and potentially arterial stiffness. 
Along with increases in arterial stiffness, we observed a significant decrease in 
cardiovagal BRS. Additionally, we observed a significant relationship between BRS and carotid 
artery stiffness. This supports previous work that observed a similar relationship in non-cancer 
popluations (43, 44). Baroreflex control of arterial blood pressure is achieved via a tonically 
active feedback loop. In a healthy individual, the arterial baroreflex will respond to increase in 
blood pressure by inhibiting sympathetic outflow. When stimulated, these baroreceptors increase 
afferent nerve firing rate, leading to increased stimulus of the nucleus tractus solitarius. This 
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subsequently leads to increased excitatory signals towards the caudal ventrolateral medulla and 
consequently increased inhibitory signals to the rostral ventrolateral medulla. This decrease in 
signaling to the rostral ventrolateral medulla causes a decrease in sympathetic outflow. 
Combining the effects of this, as well as the increased parasympathetic outflow courtesy of the 
nucleus ambiguus, results in decreases in heart rate, and vascular resistance, consequently 
leading to a decrease in blood pressure.  
Given the integrated neural control of the arterial baroreflex, it is important to consider 
that many anti-cancer chemotherapies are associated with the development of neuropathy (20, 
39, 40, 45, 55). We believe this, in combination with increased carotid artery stiffness, to be a 
likely factor in the decreased BRS observed in the cancer treatment group. To date there is a 
paucity of information regarding the effects of anti-cancer treatment on autonomic control of 
blood pressure, with limited evidence of clinical symptoms of autonomic dysfunction (i.e., 
arrhythmia, orthostatic hypotension). However, taxol chemotherapy (paclitaxel and docetaxel) 
are a subclass of chemotherapy drug that was used in five patients and has been shown to 
directly damage Schwann cells and axons of afferent neurons (4, 51). Additionally, Vinca rosea 
alkaloids in particular have been associated with neurotoxicity and/peripheral neuropathy (45), 
with one patient from the present study administered this class of drug. Additionally, the pro-
inflammatory, antioxidant sparse condition brought on by chemotherapy treatments (6, 15) may 
have exacerbate the typical stimuli required to elicit detrimental effects on BRS. Decreased BRS 
is prevalent in a variety of disease states, including; hypertension, rheumatoid arthritis, and 
peripheral artery disease (3, 35, 41). All of these diseases share two common factors; a pro-
inflammatory state, and an increase in arterial stiffness (3, 35, 41). While our evidence only can 
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support the increased stiffness, we know that anthracyclines cause high levels of inflammation 
when administered (11, 26, 41).  
 
Considerations and Limitations 
 
There are numerous considerations to make when examining these data. First, our cancer 
population was quite varied, consisting of several types of cancer across just 8 participants. 
Additionally, these patients had very little crossover as far as specific drugs used in therapy 
plans. While this combination provided far less control in terms of identifying whether or not a 
specific drug was responsible for these circulatory problems, it does allow us to identify that 
these issues occur through chemotherapy in general. The second consideration to make is sample 
size. Lastly, this study was, by design, cross-sectional instead of longitudinal. We acknowledge it 
would have been preferential to test cancer patients before and after their treatment started, but 
given that our laboratory does not function inside and along an oncology office it is quite 
difficult to find participants in such a narrow window. For these patients and their doctors, 
starting treatment in a timely manner is a top priority. Because of that we designed the study in 
such a way to allow us to examine the effects of chemotherapy during its application. We believe 
this set our data apart by showing that these detrimental effects do not take months/years to 
develop, but rather occur early in the treatment process. 
 
Conclusions 
This is the first study, to our knowledge, to report the impact of adjuvant anti-cancer 
chemotherapy on changes in artery stiffness and baroreflex control of arterial blood pressure. 
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The findings of the present study suggest that chemotherapeutic cancer therapies are detrimental 
to arterial stiffness and BRS. While the specific mechanism cannot be determined with our data, 
and are only speculative at this point, the combination of our findings with previous studies 
suggest that several factors may be contributing to these changes: including the existence of a 
pro-inflammatory state, increases in reactive oxygen species, and the progression of 
chemotherapy-induced peripheral neuropathy. Future work will need to evaluate the role each of 
these factors has in mediating the adverse changes in cardiovascular health in cancer patients 
undergoing chemotherapy.  
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